Currentblue cross blue shield - tennesseePolicy N/A

Biomarker Testing for Autoimmune Rheumatic Disease (Commercial) – G2022

Defines coverage and limitations for laboratory biomarker testing used in diagnosis and monitoring of systemic autoimmune rheumatic diseases (SARDs) including ANA, ENA, RF, anti-CCP, dsDNA, select disease-specific antibodies, and proprietary multi-biomarker panels. Specifies frequency limits, covered indications (symptomatic/diagnostic contexts), and tests considered not medically necessary or experimental.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyBiomarker Testing for Autoimmune Rheumatic Disease (Commercial) – G2022

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument signs/symptoms of autoimmune disease or clinical correlation with abnormal ANA to justify ENA, RF, anti-CCP, dsDNA, or specific antibody testing per policy frequency limits.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes

Covered w/ conditionsANA screening

ConditionalENA testing

Not coveredProprietary biomarker panels

<=4/yrdsDNA testing limit

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy addresses biomarker testing used in the diagnosis and evaluation of systemic autoimmune rheumatic diseases (SARDs), focusing on tests such as ANA, ENA, RF, anti-CCP, dsDNA, and select myositis antibodies. Coverage stance is mixed: standard autoantibody testing in appropriate clinical contexts is conditionally covered while proprietary multi-biomarker/algorithmic panels and certain investigational assays are not covered.

Surface threshold summary

dsDNA frequency<= 4 per year

ANA additional tests (lifetime)Up to 2 additional tests per lifetime

RF / anti-CCP additional tests (lifetime)Up to 2 additional tests per lifetime

Coverage stancemixed

ScopeDefines coverage and limitations for laboratory biomarker testing used in diagnosis and monitoring of systemic autoimmune rheumatic diseases (SARDs) including ANA, ENA, RF, anti-CCP, dsDNA, select disease-specific antibodies, and proprietary multi-biomarker panels. Specifies frequency limits, covered indications (symptomatic/diagnostic contexts), and tests considered not medically necessary or experimental.

Medical Necessity Criteria

Covered - Screening and diagnostic testing

Covered when ALL of the following are met:

ALL of the following

Individual has signs or symptoms of an autoimmune disease
Applies to initial screening using antinuclear antibodies (ANA)
Testing is performed once during initial workup
ANA screening limited to once during initial workup

Covered - Additional testing for new/worsening symptoms

Covered when ANY of the following are met:

ANY of the following

Up to two additional ANA tests per lifetime if new or more severe signs or symptoms of an autoimmune disease develop
Lifetime limit = initial test + up to 2 additional tests
For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies
Once during initial workup; if initial testing did not result in diagnosis of RA, up to two additional tests per lifetime if symptoms persist or additional symptoms of RA develop

Covered - Reflex/diagnostic follow-up testing when ANA abnormal

Covered when ALL of the following are met:

ALL of the following

Abnormal, raised ANA titer AND clinical correlation with the appropriate autoimmune disorder
Indication required to perform ENA panel testing of specific autoantibodies
ENA panel testing of specific autoantibodies
Meets coverage criteria when above condition satisfied; ENA panel requires abnormal ANA plus clinical correlation

Covered - dsDNA testing frequency

Covered when ALL of the following are met:

ALL of the following

Initial positive ANA test AND diagnosis of systemic autoimmune rheumatic disease
Context required for dsDNA testing
Testing of dsDNA up to four (4) times per year<= 4 per year
Frequency limit specified

Covered - Specific antibody testing with negative/low positive ANA

Covered when ANY of the following are met:

ANY of the following

Testing for anti-Jo-1 in a unique clinical subset of myositis
Testing for anti-SSA (anti-Sjögren's-syndrome-related antigen A) in the setting of lupus or Sjögren's syndrome

Not covered - Monitoring, asymptomatic, and inappropriate contexts

The following DO NOT MEET COVERAGE CRITERIA: (Not Medically Necessary)

Not Medically Necessary

Monitoring of disease with ANA testing or ANA titers
For individuals without symptoms suggestive of an autoimmune disorder, ANA and/or ENA testing
Testing of specific antibodies in the absence of a positive ANA test (unless specific covered exceptions described above apply)
For asymptomatic individuals, testing of ANA and/or ENA during a wellness visit or a general exam without abnormal findings
For the diagnosis of RA, testing for serum biomarkers not discussed above, alone or in a panel (e.g., Seronegative Rheumatoid Arthritis Profile)

Coding

Referenced / covered CPT / HCPCS / Proprietary codes (general reference)mixed

86038	Antinuclear antibodies (ANA)
86039	Antinuclear antibodies (ANA); titer
86200	Cyclic citrullinated peptide (CCP), antibody
86225	Deoxyribonucleic acid (DNA) antibody; native or double stranded
86235	Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody
86431	Rheumatoid factor; quantitative
81490	Unlisted multianalyte assay with algorithmic analysis (used to denote experimental/investigative tests e.g., Vectra® DA)
81599	Unlisted multianalyte assay with algorithmic analysis (alternate unlisted code)
0039U	Proprietary/test-specific U-code referenced (Anti-dsDNA High Salt/Avidity and others listed)
0062U	Proprietary/test-specific U-code referenced

1–10 of 14

1/2

Not covered / Experimental or Investigational testsmixedNot Covered

81490	Unlisted multianalyte assay with algorithmic analysis (used to denote experimental/investigative tests e.g., Vectra® DA)
81599	Unlisted multianalyte assay with algorithmic analysis

Provider Actions

Documentation Required

Clinical indication required for coverage

Document signs and symptoms of autoimmune disease and provide clinical correlation with abnormal ANA results to justify ENA, RF, anti-CCP, dsDNA, or specific antibody testing per policy frequency limits.

86038
86039
86200
86225
86235
86431

Prior Authorization

Potential preauthorization for proprietary/multianalyte tests

Proprietary multibiomarker panels and algorithmic assays are considered experimental/investigational and are not covered; obtain prior authorization if local policy requires when billing unlisted or proprietary test codes.

81490
81599
0039U
0062U
0312U
0446U
0447U
0521U

Denial Risk

Claims denial risk for asymptomatic or screening-only testing

Claims for ANA and/or ENA testing for asymptomatic individuals, wellness or general exams without abnormal findings, or in the absence of signs/symptoms may be denied as not meeting coverage criteria.

86038
86039
86235

Background and Definitions

Systemic autoimmune rheumatic diseases (SARDs) are a heterogeneous group of disorders (e.g., SLE, Sjögren's, MCTD, systemic sclerosis, idiopathic inflammatory myopathies) characterized by dysregulated immunity and inflammation; detection and identification of autoantibodies help support diagnosis and classification. The antinuclear antibody (ANA) assay is commonly used as an initial screening test, with extractable nuclear antigens (ENA) including Sm, U1 RNP, Ro (SS-A), and La (SS-B) used for further evaluation when clinically indicated.

Coverage is indicated for ANA screening and for reflex/diagnostic follow-up (ENA, RF, anti-CCP, dsDNA, and select disease-specific antibodies) when tied to signs/symptoms or clinical correlation per the policy. Laboratory-developed tests (LDTs) are regulated under CLIA as high-complexity tests and are not FDA-cleared/approved; proprietary multianalyte algorithmic panels (e.g., Vectra® DA, AVISE, other indexed panels) are considered experimental/investigative and are not covered. Guidance and evidence sources include professional society guidance and peer-reviewed literature (e.g., ACR, EULAR/ACR classification criteria and cited clinical studies).

Term	Definition
ENA	Extractable nuclear antigens; includes Sm, U1 RNP, Ro (SS-A), La (SS-B) and others
LDT	Laboratory-developed test; regulated by CMS under CLIA as high-complexity tests

Key guideline references: ACR position statements and classification criteria, EULAR/ACR classification criteria for SLE, and peer-reviewed studies and reviews supporting the indicated use and limitations of biomarker testing (see professional society guidelines and cited literature).

OpenPayer

Biomarker Testing for Autoimmune Rheumatic Disease (Commercial) – G2022

Coverage Summary

Medical Necessity Criteria

Coding

Provider Actions

Background and Definitions

Revision History